Al Root
GE HealthCare Technologies reported better-than-expected first-quarter earnings. That's the good news. The bad news is guidance was cut due to the impact of tariffs.
Wednesday morning, GE HealthCare reported first-quarter adjusted earnings per share of $1.01 from sales of $4.8 billion. Wall Street was looking for EPS of 91 cents from sales of $4.7 billion. A year ago, the company reported EPS of 90 cents from sales of $4.7 billion.
"First quarter results reflect strong execution as we start the year with robust revenue, orders, and profit growth, which were driven by strength in the U.S.," said CEO Peter Arduini in a news release. "Regarding the current global trade environment, we are actively driving mitigation actions."
The company can't mitigate all the trade impacts. Full-year 2025 financial guidance moved lower. Sales are still expected to grow 2% to 3% year over year, but the operating profit margins for the year should land at about 14.3%, down from prior guidance of 16.7%. Margins in 2024 were 16.3%.
Earnings per share should land between $3.90 and $4.10 a share, including an 85-cent tariff-related hit. The $4 midpoint is down from the prior midpoint of $4.68.
Wall Street currently projects 2025 EPS of $4.70.
GE HealthCare's assumption in that guidance is that current bilateral U.S.-China tariffs remain in place. The company generates roughly 10% of its sales in China.
Despite the cut, GE HealthCare shares were up 6.8% in premarket trading, while S&P 500 futures were down 0.3%, and Dow Jones Industrial Average futures were up 0.1%.
The starting point is part of the story. Coming into Wednesday trading, GE HealthCare shares were down 23% since the Nov. 5 presidential election. Tariff concerns have weighed on investor sentiment for some time.
For now, a little more detail about tariff costs has provided investors some relief.
Also helping was a new $1 billion share buyback the board just authorized.
Write to Al Root at allen.root@dowjones.com
This content was created by Barron's, which is operated by Dow Jones & Co. Barron's is published independently from Dow Jones Newswires and The Wall Street Journal.
(END) Dow Jones Newswires
April 30, 2025 07:26 ET (11:26 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.